deuruxolitinib (Leqselvi)

Indications

• severe alopecia areata (FDA-approved 2024)

* third JAK inhibitor FDA approved for severe alopecia areata

Dosage

• 8 mg PO BID
• tablets: 8 mg

Adverse effects

• headache (12.4% vs 9.4% with placebo)
• acne (10% vs 4.3% with placebo)
• nasopharyngitis (8.1% vs 6.7% with placebo).

• drug adverse effects of tyrosine kinase inhibitor(s)
• drug adverse effects of janus kinase inhibitors

Mechanism of action

• inhibits JAK1 & JAK2

More general terms

• small inhibitory antineoplastic agent (ib drug)
• Janus kinase inhibitor; JAK inhibitor

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=72704611